natgillin/translations-raw huggingface dataset:
• For patients who have already started treatment (i.e. those who have had their biopsies taken) company has made arrangements to store any existing biopsies so that treatment can be completed unless patients and their treating surgeons have explicitly indicated that they no longer wish to complete treatment with MACI. 
• Pri bolnikih, ki so že začeli zdravljenje (tj. pri katerih so že opravili biopsijo), je družba uvedla postopke za shranjevanje vseh obstoječih biopsij, tako da lahko bolnik dokonča zdravljenje, razen če bolnik in njegov lečeči kirurg izrecno navedeta, da ne želita dokončati zdravljenja z zdravilom MACI.
MACI is unavailable for new patients in the EU until a new manufacturing site has been registered in the EU. 
Zdravilo MACI ne bo na voljo novim bolnikom v EU, dokler ne bo v EU registrirano novo proizvodno mesto.
The site has now been closed and MACI remains unavailable for new patients in the EU until a new manufacturing site has been registered in the EU. 
Proizvodno mesto je zdaj zaprto, zato zdravilo MACI ne bo na voljo novim bolnikom v EU, dokler ne bo v EU registrirano novo proizvodno mesto.
Information to healthcare professionals 
Stopite v stik z našimi tiskovnimi predstavniki
(frequency cannot be estimated from the available data) 
(ni mogoče oceniti iz razpoložljivih podatkov)
Date of first authorisation: 9 March 2000 Date of latest renewal: 9 March 2010 
Datum prve odobritve: 9. marec 2000 Datum zadnjega podaljšanja: 9. marec 2010
§, increased appetite 
§, povečan apetit
- if you have severe heart disease. 
- če imate hudo srčno bolezen.
Please read the instructions carefully and follow them step by step. 
Natančno jih preberite in sledite vsakemu koraku posebej.
Any or all of these activities may contribute to interferon's therapeutic effects. 
Kateri koli ali vsi od teh učinkov lahko prispevajo k terapevtskemu delovanju interferona.
The effect on human pregnancy is not known. 
Učinek na nosečnost pri človeku ni znan.
Do not attempt to inject yourself unless you are sure you understand the procedure and requirement of self-injection. 
Zdravila pa si ne skušajte injicirati, če niste prepričani, da razumete postopek in zahteve za samoinjiciranje.
The infusion must be prepared immediately prior to use. 
Infuzijo je treba pripraviti tik pred uporabo.
• Genotype 1: The recommended duration of treatment is one year. 
• Genotip 1: Priporočeno trajanje zdravljenja je 1 leto.
There are no data on long term effects on sexual maturation. 
Ni podatkov o dolgoročnih učinkih zdravila na spolno zorenje.
- if you have advanced decompensated (uncontrolled) liver disease. 
- če imate napredovano dekompenzirano (nenadzorovano) jetrno bolezen.
Interactions between IntronA and other medicinal products have not been fully evaluated. 
Interakcij med zdravilom IntronA in drugimi zdravili še niso v celoti ovrednotili.
Need for adequate hydration 
Potreba po ustrezni hidraciji
They are produced and secreted by cells in response to viral infections or various synthetic and biological inducers. 
Izdelujejo in izločajo jih celice kot odziv na virusne okužbe ali različne sintetične ali biološke induktorje.
• Genotype 2/3: The recommended duration of treatment is 24 weeks. 
• Genotip 2/3: Priporočena dolžina zdravljenja je 24 tednov.
§, influenza-like symptoms 
§, gripi podobni simptomi
Undesirable effects were usually managed by dose adjustment. 
Neželene učinke so običajno obvladovali s prilagajanjem odmerkov.
if you have a current or previous infection with the hepatitis B virus, since your doctor may want to monitor you more closely. 
če imate ali ste imeli okužbo z virusom hepatitisa B, ker vas bo zdravnik morda želel bolj skrbno spremljati.
Studies with other interferons have demonstrated species specificity. 
Tudi raziskave z drugimi interferoni so pokazale vrstno specifičnost.
Overall Response a (n=118) 
Skupni odziv a (n=118)
For storage conditions of the medicinal product, see section 6.3. 
Za pogoje shranjevanja zdravila glejte poglavje 6.3.
Patients with advanced disease may require a daily dose of 5 million IU. 
Pri bolnikih z napredovano boleznijo je lahko potreben odmerek 5 milijonov i.e. na dan.
- if you have cirrhosis or other liver problems (other than hepatitis B or C). 
- če imate cirozo ali druge težave z jetri (razen hepatitisa B ali C).
Duration of treatment for children and adolescents 
Trajanje zdravljenja za otroke in mladostnike
6 IU/kg/day for 3 months. 
6 i.e./kg na dan 3 mesece.
Some children did not reach their projected height within 10-12 years after completing treatment. 
Nekateri otroci tudi niso dosegli pričakovane telesne višine v obdobju 10 do 12 let po zaključku zdravljenja.
Do not use IntronA - if you are allergic to interferon or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila IntronA - če ste alergični na interferon ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not use this medicine if you notice changes in the appearance of IntronA. 
Ne uporabljajte tega zdravila, če opazite spremembe videza zdravila IntronA.
(%)) in previously untreated children and adolescents by genotype and treatment duration - All subjects n = 107 24 weeks 
(%)) pri predhodno nezdravljenih otrocih in mladostnikih po genotipu in dolžini zdravljenja - vsi preizkušanci n = 107 24 tednov
- if you have thyroid disease that is not well controlled. 
- če imate bolezen ščitnice, ki ni dobro nadzorovana.
§, virilism 
§, virilizem
Laboratory Tests 
Laboratorijske preiskave
Authorized Representative: BD, Laagstraat 57, B-9140 Temse, Belgium 
Pooblaščeni predstavnik: BD, Laagstraat 57, B-9140 Temse, Belgija
The detectable titres are low in almost all cases and have not been regularly associated with loss of response or any other autoimmune phenomenon. 
Merljivi titri so majhni skoraj v vseh primerih in jih niso redno povezovali s prenehanjem odziva ali s kakršnim koli drugim avtoimunskim pojavom.
Whenever possible the child should be treated after the pubertal growth spurt, in order to reduce the risk of growth inhibition. 
Kadar koli je mogoče, je treba zdravljenje pri otroku uvesti po obdobju intenzivne rasti v puberteti, da bi zmanjšali tveganje za zastoj rasti.
The clear and colourless solution is contained in a glass vial. 
Bistra in brezbarvna raztopina je v stekleni viali.
For paediatric patients who weigh < 47 kg or cannot swallow capsules, see ribavirin oral solution SPC.) 
Za pediatrične bolnike, ki tehtajo < 47 kg ali ne morejo pogoltniti kapsul, glejte SPC za peroralno raztopino ribavirina.)
Not all dose forms and strengths are appropriate for some indications. 
Vse farmacevtske oblike in jakosti niso primerne za vse indikacije.
6 IU/kg/day for 3 months caused no remarkable toxicity. 
6 i.e./kg na dan 3 mesece ni povzročilo pomembne toksičnosti.
Patients should be closely monitored for any signs or symptoms of psychiatric disorders. 
Bolnike je treba skrbno spremljati, da se ugotovi morebitne znake ali simptome psihiatričnih motenj.
Another 4 % had a transient decrease below the lower limit of normal. 
Pri nadaljnjih 4 % bolnikov je prišlo do prehodnega zmanjšanja vrednosti pod spodnjo mejo normale.
Insert the needle into the pinched skin at an angle of 45° to 90°. 
Iglo vbodite v kožno gubo pod kotom 45 do 90.
This will lessen the chance for ribavirin to be left in the woman's body. 
Tako boste zmanjšali možnost za prehajanje ribavirina v telo ženske.
Although the optimal (minimum) dose for full clinical benefit is unknown, patients must be treated at the recommended dose, with dose reduction for toxicity as described. 
Čeprav optimalni (minimalni) odmerek za doseganje polnega kliničnega učinka ni znan, morate bolnike zdraviti s priporočenim odmerkom, z opisanim zmanjšanjem odmerka v primeru toksičnosti.
The optimal duration of therapy with IntronA alone is not yet fully established, but a therapy of between 12 and 18 months is advised. 
Optimalna dolžina zdravljenja z zdravilom IntronA samim še ni bila dokončno ugotovljena, vendar svetujemo, naj zdravljenje traja od 12 do 18 mesecev.
Other in-use storage times and conditions are the responsibility of the user. 
Za čas shranjevanja in druge pogoje shranjevanja zdravila med uporabo je odgovoren uporabnik.
Table 6 Sustained virological response rates (n a,b 
Preglednica 6 Deleži trajnega virološkega odziva (n a,b
Although interferon is generally recognised as being species specific, toxicity studies in animals were conducted. 
Čeprav interferon na splošno velja za vrstno specifičnega, so bile opravljene predklinične raziskave toksičnosti na živalih.
IntronA is usually intended for subcutaneous use. 
Zdravilo IntronA je običajno namenjeno subkutani uporabi.
It has demonstrated significant immunomodulatory activity in vitro. 
In vitro je pokazal znatno imunomodulatorno delovanje.
Treatment must be initiated by a physician experienced in the management of the disease. 
Zdravljenje mora uvesti zdravnik z izkušnjami pri zdravljenju bolezni.
IntronA is given either daily (5 or 7 times a week), or three times a week, every other day, for example on Monday, Wednesday, and Friday. 
Zdravilo IntronA se daje bodisi vsak dan (5 ali 7-krat na teden), ali 3-krat na teden vsak drugi dan, na primer v ponedeljek, sredo in petek.
Efficacy was defined as sustained virologic response, 6 months after the end of treatment. 
Učinkovitost so opredelili kot trajen virološki odziv 6 mesecev po koncu zdravljenja.
This means that IntronA is injected with a short needle into the fatty tissue just under the skin. 
To pomeni, da se injicira s kratko iglo v maščobno tkivo tik pod kožo.
§, hyperuricemia, increased appetite 
§, hiperurikemija, povečan apetit
The usual starting dose for each condition follows; however, individual doses may vary, and the doctor may change your dose based on your specific needs: 
Običajni začetni odmerki za posamezne bolezni ali motnje so navedeni v nadaljevanju, vendar pa posamezni odmerki lahko odstopajo in zdravnik lahko spremeni vaš odmerek glede na vaše specifične potrebe:
Seventy percent (68/97) of all enrolled subjects completed this study of which 75 % (42/56) were sustained responders. 
70 % (68/97) vseh v študijo vključenih preizkušancev je študijo dokončalo in od tega jih je 75 % (42/56) doseglo trajni virološki odziv.
IntronA is to be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. 
Zdravilo IntronA uporabljajte v času nosečnosti le, če njegove potencialne koristi upravičijo potencialno tveganje za plod.
If you have the impression that the effect of IntronA is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila IntronA premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
If the solution is cold, warm the syringe between your palms. 
Če je raztopina hladna, brizgo ogrejte v dlaneh.
Pulmonary arterial hypertension - a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. 
Pljučna arterijska hipertenzija - bolezen, ki povzroči hudo zoženje krvnih žil v pljučih, katerega posledica je visok krvni tlak v žilah, po katerih kri teče iz srca v pljuča.
a: Response to treatment was defined as undetectable HCV-RNA at 24 weeks post-treatment, lower limit of detection=125 IU/mL. 
a: Odziv na zdravljenje je bil opredeljen kot nemerljiva vrednost HCV-RNA v 24. tednu po zdravljenju, spodnja meja detekcije = 125 i.e./ml.
Moderate and usually reversible reduction in all three blood elements-white blood cells, red blood cells and platelets, has been reported. 
Poročali so o zmernem in ponavadi reverzibilnem zmanjšanju števila vseh treh vrst krvnih celic- belih krvnih celic, rdečih krvnih celic in celic za strjevanje krvi.
Psychiatric and central nervous system: 
Psihiatrične motnje in centralni živčni sistem:
If intolerance persists after dose adjustment or if granulocytes decrease to < 250/mm 
Če intoleranca traja tudi po prilagoditvi odmerka ali če število granulocitov upade na < 250/mm
Moreover children treated with interferon alfa-2b experienced a reduced rate of growth and some cases of depression were observed. 
Poleg tega so pri otrocih, zdravljenih interferonom alfa-2b, opazili zmanjšano hitrost rasti in nekaj primerov depresije.
As maintenance therapy in patients who have achieved objective remission (more than 50 % reduction in myeloma protein) following initial induction chemotherapy. 
Kot vzdrževalno zdravljenje pri bolnikih, pri katerih je bila dosežena objektivna remisija (več kot 50 % zmanjšanje količine mielomskega proteina) po začetni uvajalni kemoterapiji.
There are no data in children or adolescents with a history of cardiac disease. 
Podatkov o otrocih in mladostnikih s srčno boleznijo v anamnezi ni.
However, this does not preclude the occurrence of hepatic events in patients with cirrhosis (including hepatocarcinoma). 
To pa ne izključuje pojava jetrnih dogodkov pri bolnikih s cirozo (vključno s hepatokarcinomom).
All patients in these trials received 3 MIU of IntronA three times a week. 
Vsi bolniki v teh preskušanjih so prejemali 3 milijone i.e. zdravila IntronA trikrat na teden.
The pharmacokinetics of IntronA and ribavirin (dose-normalized) are similar in adults and children or adolescents. 
Farmakokinetika zdravila IntronA in ribavirina (z normaliziranim odmerkom) je podobna pri odraslih in otrocih ali mladostnikih.
Do not use this medicine after the expiry date which is stated on the package. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Genotype 1  2 million copies/mL Genotype 1 > 2 million copies/mL 
Genotip 1  2 milijona kopij/ml Genotip 1 > 2 milijona kopij/ml
- if you have hepatitis and have been treated recently with medicines that suppress the immune system (other than short-term treatment with cortisone-type medicine). 
- če imate hepatitis in ste se nedavno zdravili z zdravili, ki zavirajo imunski sistem (razen kratkotrajnega zdravljenja z zdravili, kot je kortizon).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
V posameznih skupinah glede pogostnosti so neželeni učinki navedeni po padajoči resnosti.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Cases of stroke (cerebrovascular events) have been reported. 
Poročali so o primerih možganske kapi (cerebrovaskularni dogodki).
Long-term efficacy data 
Dolgoročni podatki o učinkovitosti
For multidose vials, be sure to return the vial to the refrigerator. 
Pri uporabi viale z več odmerki ne pozabite viale po uporabi vrniti nazaj v hladilnik.
If your female partner is not pregnant now but is of childbearing age, she must be tested for pregnancy each month during treatment and for the 7 months after treatment has stopped. 
Če vaša partnerka trenutno ni noseča, a je v rodni dobi, mora opraviti nosečnostni test vsak mesec med vašim zdravljenjem in še 7 mesecev po koncu zdravljenja.
Response rates in these trials were increased with compliance. 
Deleži odziva v teh raziskavah so se povečevali s komplianco zdravljenja.
Warnings and precautions Talk to your doctor, pharmacist or nurse before using IntronA - if you are pregnant or planning to become pregnant (see section “Pregnancy and breast-feeding”). 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila IntronA se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro - če ste noseči ali načrtujete nosečnost (glejte poglavje “Nosečnost in dojenje”).
If the product is not used during the seven-day period, it cannot be put back in the refrigerator for a new storage period and must be discarded. 
Če zdravila ne porabite v teh 7 dneh, ga ne smete postaviti nazaj v hladilnik za naslednje obdobje shranjevanja, ampak ga morate zavreči.
Pharmacotherapeutic group: interferon alfa-2b, ATC code: L03A B05 
Farmakoterapevtska skupina: interferon alfa-2b, oznaka ATC: L03A B05
The response to treatment in both of these trials is presented in Table 4. 
Odzivi na zdravljenje v obeh študijah so podani v Preglednici 4.
Growth rate decrease (height and/or weight decrease for age) 
zmanjšana rast (premajhna telesna višina in/ali masa glede na starost)
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden začnete uporabljati to zdravilo.
- if you notice unusual bleeding or bruising check with your doctor immediately. 
- če opazite nenavadne krvavitve ali podplutbe, se nemudoma posvetujte z zdravnikom.
All patients were followed for an additional 6 months after the end of treatment for the determination of sustained virologic response. 
Vse bolnike so spremljali še nadaljnjih 6 mesecev po koncu zdravljenja, da so ugotavljali trajen virološki odziv.
Please make sure to select an appropriate dose form and strength. 
Prosimo, pozorno izberite primerno obliko in jakost.
You should brush your teeth thoroughly twice daily and have regular dental examinations. 
Temeljito si morate ščetkati zobe dvakrat na dan in redno hoditi na pregled k zobozdravniku.
IntronA treatment must be discontinued after 8 to 12 weeks of treatment if at least a partial haematological remission or a clinically meaningful cytoreduction has not been achieved. 
Terapijo z zdravilom IntronA morate po 8 do 12 tednih prekiniti, če niste dosegli vsaj delne hematološke remisije ali klinično pomembnega zmanjšanja števila celic.
Therefore, the combination of IntronA with telbivudine is contraindicated (see section 4.3). 
Kombinacija zdravila IntronA in telbivudina je zato kontraindicirana (glejte poglavje 4.3).
If you are scheduled to inject this medicine every day, and you accidentally missed a full day's dose, continue treatment at the usual dose the following day. 
Če si zdravilo injicirate vsak dan in ste nehote pozabili celodnevni odmerek, naslednji dan nadaljujte zdravljenje z običajnim odmerkom.
What you need to know before you use IntronA 
Kaj morate vedeti, preden boste uporabili zdravilo IntronA
If you forget to use IntronA 
Če ste pozabili uporabiti zdravilo IntronA
Any unused medicine must be discarded after withdrawal of the dose. 
Neporabljeno zdravilo je potrebno zavreči potem, ko vzamete odmerek.
Narcotics, hypnotics or sedatives must be administered with caution when used concomitantly with IntronA. 
Narkotike, hipnotike ali sedative morate pri sočasni uporabi z zdravilom IntronA uporabljati previdno.
A major cytogenetic response is defined by < 34 % Ph+ leukaemic cells in the bone marrow, whereas a minor response is  34 %, but < 90 % Ph+ cells in the marrow. 
Večji citogenetski odziv je opredeljen kot < 34 % Ph+ levkemičnih celic v kostnem mozgu, manjši pa kot  34 %, vendar z < 90 % Ph+ celic v kostnem mozgu.
Patients with psoriasis and sarcoidosis 
Bolniki s psoriazo in sarkoidozo
Preparation of IntronA for intravenous infusion: The infusion is to be prepared immediately prior to use. 
Priprava zdravila IntronA za intravensko infundiranje: Infuzijo morate pripraviti tik pred uporabo.
Immediately contact the doctor or seek emergency treatment if they display any unusual behavioural symptoms, feel depressed, or feel they want to harm themselves or others. 
Takoj pokličite zdravnika ali poiščite nujno medicinsko pomoč, če otrok kaže kakršne koli neobičajne vedenjske znake, se počuti depresivno ali če otrok želi škodovati sebi ali drugim.
Be sure the solution is at room temperature up to 25°C. 
Raztopina mora biti na sobni temperaturi do 25 °C.
Patients who fail to achieve virological response at 12 weeks are highly unlikely to become sustained virological responders (negative predictive value 96 %). 
Pri bolnikih, ki niso dosegli virološkega odziva v 12. tednu, je zelo majhna verjetnost, da bodo dosegli trajen virološki odziv (negativna napovedna vrednost 96 %).
IntronA 3 MIU/m 2 3 times a week (n = 54) 
IntronA 3 mio i.e./m 2 3-krat na teden (n = 54)
A five-year long-term, observational, follow-up study enrolled 97 paediatric chronic hepatitis C patients after treatment in the standard interferon multicentre trials. 
V petletno dolgoročno opazovalno študijo za spremljanje bolnikov so vključili 97 pediatričnih bolnikov s kroničnim hepatitisom C po zdravljenju v okviru multicentričnih preskušanj s standardnim interferonom.
It is recommended that patients be treated with IntronA alone for at least 3 to 4 months, at which point HCV-RNA status should be determined. 
Priporočamo, da bolnike zdravite z zdravilom IntronA samim najmanj 3 do 4 mesece, potem pa določite stanje HCV-RNA.
Your doctor will monitor you for signs and symptoms of these conditions (Please be sure to read the ribavirin Patient Leaflet also). 
Zdravnik vas bo spremljal, da ugotovi morebitne znake in simptome teh motenj (Preberite si tudi Navodilo za uporabo za ribavirin).
The Kaplan-Meier estimate for continued sustained response over 5 years for all patients is 97 % with a 95 % Confidence Interval of [95 %, 99 %]. 
Kaplan-Meierjeva ocena ohranjanja trajnega virološkega odziva v obdobju 5 let za vse bolnike znaša 97 %, s 95 % intervalom zaupanja [95 %, 99 %].
If you are prescribed IntronA in combination with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur: - if you are a girl or a woman of childbearing age, you must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment is stopped. 
Če vam zdravnik predpiše IntronA v kombinaciji z ribavirinom, je ribavirin lahko zelo škodljiv za nerojenega otroka, zato morajo tako bolnice kot bolniki upoštevati posebne previdnostne ukrepe glede spolnih odnosov, če obstaja kakršna koli možnost za zanositev: - če ste dekle ali ženska v rodni dobi, mora biti nosečnostni test pri vas negativen pred zdravljenjem, vsak mesec med zdravljenjem in še 4 mesece po zaključku zdravljenja.
Regardless of genotype, patients who received IntronA in combination with ribavirin and received  80 % of their treatment had a higher sustained response 6 months after 1 year of treatment than those who took < 80 % of their treatment (56 % vs. 32 % in trial C/I98-580). 
Ne glede na genotip so imeli bolniki, ki so prejemali IntronA skupaj z ribavirinom in so prejeli  80 % terapije, večji trajen odziv 6 mesecev po enoletnem zdravljenju kot tisti, ki so prejeli < 80 % terapije (56 % v primerjavi z 32 % v raziskavi C/I98-580).
If this is a multidose vial, you will only have to remove the cap when preparing the first dose. 
Če gre za vialo z več odmerki, je treba kapico sneti le pri pripravi prvega odmerka.
The mechanism behind these events is not known (see sections 4.3, 4.4 and 4.5 of the telbivudine SPC). 
Mehanizem nastanka periferne nevropatije ni znan (glejte poglavja 4.3, 4.4 in 4.5 v SPC-ju za telbivudin).
If you have them, you may have had a serious allergic reaction to IntronA. 
Če jih imate, je možno, da imate resno alergijsko reakcijo na zdravilo IntronA.
If the medicine is not used during the seven-day period, it should be discarded. 
Če zdravila v teh 7 dneh ne uporabite, ga morate zavreči.
- if you have poor kidney or liver function. 
- če vam ledvice ali jetra slabo delujejo.
Women of childbearing potential/contraception in males and females Women of childbearing potential have to use effective contraception during treatment. 
Ženske v rodni dobi/kontracepcija pri moških in ženskah Ženske v rodni dobi morajo med zdravljenjem uporabljati učinkovito kontracepcijo.
Other medicines and IntronA 
Druga zdravila in zdravilo IntronA
If you use more IntronA than you should Contact your doctor or healthcare professional as soon as possible. 
Če ste uporabili večji odmerek zdravila IntronA, kot bi smeli Čim prej pokličite zdravnika ali drugega zdravstvenega delavca.
Interferon alfa-2b treatment is to be restarted at 50 % of the previous dose. 
Zdravljenje z interferonom alfa-2b ponovno uvedite z le 50 % prejšnjega odmerka.